| 商品名称 | 适用类别 | 通用名称 | 活性成分 | 产品号 | 上市许可开发者/申请人/持有人 | 上市许可日期 | 许可状态 |
|---|---|---|---|---|---|---|---|
| Epruvy (previously Ranibizumab Midas) | Human | ranibizumab | ranibizumab | EMEA/H/C/006528 | Midas Pharma GmbH | 2024/09/19 | Authorised |
| Rimmyrah | Human | ranibizumab | ranibizumab | EMEA/H/C/006055 | Qilu Pharma Spain S.L. | 2024/01/05 | Authorised |
| Ximluci | Human | ranibizumab | ranibizumab | EMEA/H/C/005617 | STADA Arzneimittel AG | 2022/11/09 | Authorised |
| Ranivisio | Human | ranibizumab | ranibizumab | EMEA/H/C/005019 | Midas Pharma GmbH | 2022/08/25 | Authorised |
| Byooviz | Human | ranibizumab | ranibizumab | EMEA/H/C/005545 | Samsung Bioepis NL B.V. | 2021/08/18 | Authorised |
| Lucentis | Human | ranibizumab | ranibizumab | EMEA/H/C/000715 | Novartis Europharm Limited | 2007/01/22 | Authorised |
| Ranluspec | Human | ranibizumab | ranibizumab | EMEA/H/C/006502 | Lupin Europe GmbH | Opinion | |
| Susvimo | Human | ranibizumab | ranibizumab | EMEA/H/C/005610 | Roche Registration GmbH | Application withdrawn |
请输入需要查询的英文药品名称,通用名称,活性成分,产品号
药物在线相关数据库
